Giant-Cell Arteritis Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys AG

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Giant-Cell Arteritis pipeline constitutes 6+ key companies continuously working towards developing 6+ Giant-Cell Arteritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Giant-Cell Arteritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Giant-Cell Arteritis Market.

The Giant-Cell Arteritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Giant-Cell Arteritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight [https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key takeaways from the Giant-Cell Arteritis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Giant-Cell Arteritis treatment therapies with a considerable amount of success over the years.

*
Giant-Cell Arteritis companies working in the treatment market are AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others, are developing therapies for the Giant-Cell Arteritis treatment

*
Emerging Giant-Cell Arteritis therapies in the different phases of clinical trials are- Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others are expected to have a significant impact on the Giant-Cell Arteritis market in the coming years.

*
In January 2026, Celltrion Inc., a leading South Korean biopharmaceutical company, announced that its new biosimilar for autoimmune disease treatment has been approved by the U.S. FDA. The FDA cleared Avtozma, a biosimilar to Actemra, in both intravenous and subcutaneous formulations. Avtozma is indicated for the treatment of multiple autoimmune conditions, including rheumatoid arthritis, giant cell arteritis, and also for COVID-19.

*
In July 2025, Novartis' Cosentyx (secukinumab) did not demonstrate efficacy in a Phase III trial for adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN study (NCT04930094), Cosentyx was assessed alongside a 26-week steroid taper and compared to placebo with a 52-week steroid taper. The treatment failed to achieve a statistically significant improvement in sustained remission at week 52, which was the trial's primary endpoint.

*
In April 2025, AbbVie (NYSE: ABBV) announced that the U.S. FDA has approved RINVOQ Registered (upadacitinib) 15 mg once daily for treating adults with giant cell arteritis (GCA). This follows recent European Commission approval for marketing RINVOQ in adult GCA patients. The approvals are based on results from the pivotal Phase 3 SELECT-GCA trial, which achieved its primary endpoint of sustained remission: 46.4% of patients receiving RINVOQ 15 mg with a 26-week steroid taper maintained remission from week 12 to week 52, compared to 29.0% of patients on placebo with a 52-week steroid taper (p=0.002)

*
In April 2025, A treatment regimen of Rinvoq (upadacitinib) combined with a 26-week glucocorticoid taper demonstrated superior efficacy in maintaining remission and reducing disease flares compared to placebo with a 52-week glucocorticoid taper in patients with giant-cell arteritis, according to Phase III SELECT-GCA trial (NCT03725202) results published in The New England Journal of Medicine. Currently, the only FDA-approved therapy for giant-cell arteritis is the IL-6 receptor inhibitor Actemra (tocilizumab). While glucocorticoids remain the standard treatment, their use is associated with a higher risk of toxic adverse effects (AEs).

Giant-Cell Arteritis Overview

Giant-Cell Arteritis (GCA), also known as temporal arteritis, is an inflammatory condition that affects the blood vessels, particularly the large and medium-sized arteries in the head, including the temporal arteries. It primarily affects older adults, typically over the age of 50. The inflammation can lead to symptoms such as severe headaches, scalp tenderness, vision problems, and jaw pain while chewing. If left untreated, GCA can lead to serious complications, including permanent vision loss. The condition is typically treated with corticosteroids to reduce inflammation and prevent complications.

Explore the latest Giant-Cell Arteritis pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Giant-Cell Arteritis Clinical Trials [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Giant-Cell Arteritis Drugs Under Different Phases of Clinical Development Include:

*
Rinvoq(upadacitinib): AbbVie

*
Cosentyx (secukinumab): Novartis

*
KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals

*
Tremfya(guselkumab): Johnson & Johnson/ MorphoSys AG

*
Baricitinib: Eli Lilly and Company

*
Tocilizumab + Glucocorticoids (GCs): Roche Pharma

*
Secukinumab: Novartis

*
Guselkumab: Janssen Research & Development

*
Tocilizumab: Hoffmann-La Roche

*
adalimumab: Abbott

*
Upadacitinib: AbbVie

Giant-Cell Arteritis Route of Administration

Giant-Cell Arteritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Giant-Cell Arteritis Molecule Type

Giant-Cell Arteritis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Giant-Cell Arteritis Pipeline Therapeutics Assessment

*
Giant-Cell Arteritis Assessment by Product Type

*
Giant-Cell Arteritis By Stage and Product Type

*
Giant-Cell Arteritis Assessment by Route of Administration

*
Giant-Cell Arteritis By Stage and Route of Administration

*
Giant-Cell Arteritis Assessment by Molecule Type

*
Giant-Cell Arteritis by Stage and Molecule Type

DelveInsight's Giant-Cell Arteritis Report covers around 6+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Giant-Cell Arteritis product details are provided in the report. Download the Giant-Cell Arteritis pipeline report to learn more about the emerging Giant-Cell Arteritis therapies [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Giant-Cell Arteritis Therapeutics Market include:

Key companies developing therapies for Giant-Cell Arteritis are - Novartis, CSL, Kiniksa Pharmaceuticals, AbbVie, Johnson & Johnson, MorphoSys AG, and others.

Giant-Cell Arteritis Pipeline Analysis:

The Giant-Cell Arteritis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Giant-Cell Arteritis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Giant-Cell Arteritis Treatment.

*
Giant-Cell Arteritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Giant-Cell Arteritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Giant-Cell Arteritis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Giant-Cell Arteritis drugs and therapies [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Giant-Cell Arteritis Pipeline Market Strengths

*
Improved and clear treatment and diagnostic guidelines has led the patients and practitioners to clearly diagnose and treat the patients accurately.

*
While glucocorticoids remain the primary treatment, there is ongoing research into alternative and adjunctive therapies, such as biologic agents like tocilizumab. This diversification in treatment options provides more tailored approaches for patients, considering factors like side effects and individual response.

Giant-Cell Arteritis Pipeline Market Opportunities

*
The development of targeted biologic therapies offers a significant opportunity for improving treatment outcomes in GCA. Biologics, such as interleukin-6 (IL-6) inhibitors like tocilizumab, have shown promise in clinical trials. Further research and development in this area can lead to more effective and targeted treatments.

*
The introduction of biosimilars for existing therapies can increase competition, potentially reducing treatment costs and improving accessibility for patients.

Scope of Giant-Cell Arteritis Pipeline Drug Insight

*
Coverage: Global

*
Key Giant-Cell Arteritis Companies: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others

*
Key Giant-Cell Arteritis Therapies: Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others

*
Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis current marketed and Giant-Cell Arteritis emerging therapies

*
Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers

Request for Sample PDF Report for Giant-Cell Arteritis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Giant-Cell Arteritis Report Introduction

2. Giant-Cell Arteritis Executive Summary

3. Giant-Cell Arteritis Overview

4. Giant-Cell Arteritis- Analytical Perspective In-depth Commercial Assessment

5. Giant-Cell Arteritis Pipeline Therapeutics

6. Giant-Cell Arteritis Late Stage Products (Phase II/III)

7. Giant-Cell Arteritis Mid Stage Products (Phase II)

8. Giant-Cell Arteritis Early Stage Products (Phase I)

9. Giant-Cell Arteritis Preclinical Stage Products

10. Giant-Cell Arteritis Therapeutics Assessment

11. Giant-Cell Arteritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Giant-Cell Arteritis Key Companies

14. Giant-Cell Arteritis Key Products

15. Giant-Cell Arteritis Unmet Needs

16 . Giant-Cell Arteritis Market Drivers and Barriers

17. Giant-Cell Arteritis Future Perspectives and Conclusion

18. Giant-Cell Arteritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=giantcell-arteritis-pipeline-2025-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-abbvie-novartis-csl-kiniksa-pharma-eli-lilly-roche-johnson-johnson-morphosys-ag]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.